Home / Recalls / Central Admixture Pharmacy Services, Inc. / D-0618-2026

D-0618-2026 Class II Ongoing

Recalled by Central Admixture Pharmacy Services, Inc. — Woburn, MA

FDA drug recall D-0618-2026 was initiated by Central Admixture Pharmacy Services, Inc. on June 2, 2026 and is designated Class II. Reason for recall: Incorrect product formulation: bag did not contain copper and famotidine per label. The recall status is ongoing. Affected quantity: One (1) patient-specific TPN prescription..

Recall Details

Product Type
Drugs
Report Date
July 1, 2026
Initiation Date
June 2, 2026
Termination Date
N/A
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
One (1) patient-specific TPN prescription.

Product Description

Total Parental Nutrition - Pediatric PN Patient-Specific TPN Bag, (patient specific), Rx# 24-1269856-0-1Compound Volume 1295 mL per bag, Rx only, Single Dose Injection, Refrigerated Injection, Central Admixture Pharmacy Services, Boston, 55 6th Rd Woburn, Massachusetts 01801-1767.

Reason for Recall

Incorrect product formulation: bag did not contain copper and famotidine per label.

Distribution Pattern

MA

Code Information

24-1269856-0-1

Other recalls by Central Admixture Pharmacy Services, Inc.

  • D-0272-2025 Class I — PHENYLephrine added to 0.9% sodium chloride, 40 mg/250 mL* (160 mcg/mL), Rx Only (February 20, 2025)
  • D-0007-2024 Class II — PHENYLephrine in 0.9% sodium chloride, 1,000 mcg/10 mL, (100 mcg/mL), 10 mL syri (September 21, 2023)
  • D-0028-2024 Class II — HYDROmorphone in 0.9% sodium chloride, 10 mg/50 mL, (0.2 mg/mL), 50 mL Syringe, (September 21, 2023)
  • D-0016-2024 Class II — fentaNYL 2 mcg/mL and bupivacaine 0.0625% PF in 0.9% sodium chloride, Total Volu (September 21, 2023)
  • D-0020-2024 Class II — fentaNYL, 250 mcg/5 mL, (50 mcg/mL), 5 mL Syringe, Rx only, Repackaged by CAPS I (September 21, 2023)
  • D-0009-2024 Class II — fentaNYL in 0.9% sodium chloride, 10 mcg/1 mL, (10 mcg/mL), 3 mL Syringe, Rx onl (September 21, 2023)
  • D-0013-2024 Class II — fentaNYL in 0.9% sodium chloride, 2,500 mcg/250 mL, (10 mcg/mL), 250 mL bag, Rx (September 21, 2023)
  • D-0018-2024 Class II — midazolam in dextrose 5%, 50 mg/50 mL, (1 mg/mL), 50 mL Syringe, Rx only, Centra (September 21, 2023)
  • D-0027-2024 Class II — HYDROmorphone in 0.9% sodium chloride, 6 mg/30 mL, (0.2 mg/mL), 30 mL Syringe, R (September 21, 2023)
  • D-0029-2024 Class II — HYDROmorphone in 0.9% sodium chloride, 15 mg/30 mL, (0.5 mg/mL), 30 mL Syringe, (September 21, 2023)

FDA data resources